CEVEC grants license to Biotest AG for production of tailor-made glycoproteins

Cologne, Germany, July 1, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), an expert for the production of glyco-optimized biopharmaceuticals, today announced that it has granted a license for its proprietary CAP®Go technology to Biotest AG for the development, production and commercialization of candidate molecules to treat the symptoms of hemophilia patients.

Under the terms of the license agreement, CEVEC will receive service fees for ongoing development support, upfront and milestone payments as well as royalties on future product sales.

“With Biotest, we have found an important partner for our unique CAP®Go expression system,” commented Frank Ubags, Chief Executive Officer of CEVEC Pharmaceuticals GmbH. “We consider Biotest’s commitment as a significant endorsement of our CAP® Go technology.”

About Biotest

Biotest AG is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, hematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

About CEVEC:

Privately held CEVEC is an expert for the production of tailor-made recombinant glyco-proteins and gene therapy vectors based in Cologne, Germany. The Company’s technologies, CAP®Go and CAP®GT are based on a unique human cell expression system.

The CAP®Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. The cells are highly efficient for the production of a broad range of difficult to express glycoproteins and provide authentic human post-translational modifications. CAP®Go has proven to enhance the activity, stability and serum half-life of several candidate proteins.

The CAP®GT expression platform provides a fully scalable, regulatory endorsed production system for gene therapy vectors. CAP®GT cells grow to high cell densities show a broad viral propagation spectrum including lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV). Furthermore, CAP®GT enables easier scale-up and reduced production costs when compared to adherent cell culture systems.

Research collaborations with international pharmaceutical and biotechnology partners followed by licensing agreements for the technology forms one revenue base for CEVEC. In addition, the Company provides contract manufacturing for the cGMP production in CAP®Go and CAP®GT cells.


CEVEC Pharmaceuticals GmbH
Frank Ubags
Chief Executive Officer
T.:+49 221 46020800
E.: ubags@cevec.com

MC Services AG
Anne Hennecke
Public Relations
T.: +49 211 52925222
E.: anne.hennecke@mc-services.eu